In conclusion, this thesis presents several studies to evaluate the impact of older age on clinical use and PK and PD of various anticancer treatment options. For the majority of drugs, PK and PD do not appear to be altered in the aging patient population. A priori dose reductions solely based on age are, therefore, not advisable and may threaten optimal treatment outcome. For some highly toxic treatments, such as docetaxel, intensified monitoring and use of prophylactic granulocyte colony-stimulating factors in elderly patients may improve treatment tolerability and ultimately survival. Although there is still a paucity of data to draw firm conclusions on the impact of older age on several anticancer drugs, enrollment of elderly patients in oncological pivotal trials seems to have improved. For checkpoint inhibitors, the age distribution of the pivotal trial cohorts appears to be representative for those treated with these drugs as part of clinical care. This is promising and will hopefully accelerate knowledge on the impact of older age on PK and PD of new anticancer drugs.
5 September 2019 from 10:30 to 11:30
PhD Defence: Pharmacokinetics and Pharmacodynamics in Geriatric Oncology
Start date and time5 September 2019 10:30
End date and time5 September 2019 11:30
PhD candidateMarie-Rose Bérénice Stéphanie Crombag
DissertationPharmacokinetics and Pharmacodynamics in Geriatric Oncology
PhD supervisor(s)Prof. A.D.R. HuitemaProf. J.H. Beijnen